UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 10-Q

☑   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

OR
☐   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to ___________________.

Commission file number:

PROTOKINETIX, INCORPORATED
(Exact name of registrant as specified in its charter) 


Nevada
 
94-3355026
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)

 
412 Mulberry St.
Marietta, Ohio 45750
 
 
(Address of principal executive offices)
 

 
304-299-5070
 
 
(Registrant’s telephone number, including area code)
 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer    ☐
 
Accelerated filer                     ☐
Non-accelerated filer      ☐
(Do not check if a smaller reporting company)
Smaller reporting company   ☒
Emerging growth company   ☐
   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).        Yes  ☐ No ☒

As of October 25, 2018, there were 257,952,433 shares of ProtoKinetix, Incorporated that were issued and outstanding.





PROTOKINETIX, INCORPORATED
TABLE OF CONTENTS


PART I
     
       
FINANCIAL INFORMATION
     
       
Item 1. Financial Statements
   
3
 
         
Unaudited Condensed Balance Sheets
   
3
 
         
Unaudited Condensed Statements of Operations
   
4
 
         
Unaudited Condensed Statement of Stockholders’ Equity
   
5
 
         
Unaudited Condensed Statements of Cash Flows
   
6
 
         
Notes to Unaudited Condensed Financial Statements
   
7
 
         
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
   
20
 
         
Item 3. Quantitative and Qualitative Disclosures About Market Risk
   
23
 
         
Item 4. Controls and Procedures
   
24
 
         
PART II
       
         
OTHER INFORMATION
       
         
Item 1. Legal Proceedings
   
25
 
         
Item 1A. Risk Factors
   
25
 
         
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
   
25
 
         
Item 3. Defaults Upon Senior Securities
   
25
 
         
Item 4. Mine Safety Disclosure
   
25
 
         
Item 5. Other Information
   
25
 
         
Item 6. Exhibits
   
26
 
         
Signatures
   
27
 
         
 
2



PROTOKINETIX, INCORPORATED
(A Development Stage Company)
BALANCE SHEETS
(Unaudited)

   
September 30, 2018
   
December 31, 2017
 
ASSETS
           
Current Assets
           
Cash
 
$
110,497
   
$
302,942
 
Prepaid expenses and deposits (Notes 3 and 11)
   
11,084
     
62,127
 
Total current assets
   
121,581
     
365,069
 
                 
Intangible assets (Note 4)
   
178,724
     
153,028
 
                 
Total assets
 
$
300,305
   
$
518,097
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current Liabilities
               
Accounts payable and accrued liabilities
 
$
5,020
   
$
26,906
 
Promissory notes payable (Note 10)
   
-
     
117,656
 
Total current liabilities
   
5,020
     
144,562
 
Stockholders’ Equity
               
Common stock, $0.0000053 par value; 400,000,000 common shares authorized;
257,952,433 and 251,352,433 shares issued and outstanding as at September 30, 2018 and
December 31, 2017 respectively (Note 9)
   
1,379
     
1,344
 
Additional paid-in capital
   
31,450,486
     
30,506,094
 
Accumulated deficit
   
(31,156,580
)
   
(30,133,903
)
Total stockholders’ equity
   
295,285
     
373,595
 
Total liabilities and stockholders’ equity
 
$
300,305
   
$
518,097
 
                 
Basis of Presentation – Going Concern Uncertainties (Note 1)
Commitments and Contingency (Note 11)

 

See Notes to Financial Statements
 
3


PROTOKINETIX, INCORPORATED
(A Development Stage Company)
STATEMENTS OF OPERATIONS
(Unaudited)
For the Nine Months Ended September 30, 2018 and 2017

   
Three months ended
September 30, 2018
   
Three months ended
September 30, 2017
   
Nine months ended
September 30, 2018
   
Nine months ended
September 30, 2017
 
                         
EXPENSES
                       
Amortization – intangible assets (Note 4)
 
$
750
   
$
750
   
$
2,250
   
$
2,250
 
General and administrative
   
13,723
     
12,500
     
56,757
     
74,437
 
Professional fees (Note 10)
   
30,001
     
42,549
     
98,274
     
109,823
 
Research and development
   
92,823
     
72,857
     
247,896
     
228,130
 
Share-based compensation (Notes 7 and 10)
   
234,476
     
170,536
     
614,427
     
587,077
 
                                 
     
(371,773
)
   
(299,192
)
   
(1,019,604
)
   
(1,001,717
)
                                 
                                 
OTHER ITEM
                               
Foreign exchange loss
   
(2
)
   
(100
)
   
(3,073
)
   
(4,334
)
                                 
Net loss for the period
 
$
(371,775
)
 
$
(299,292
)
 
$
(1,022,677
)
 
$
(1,006,051
)
                                 
Net loss per common share (basic and diluted)
 
$
(0.00
)
 
$
(0.00
)
 
$
(0.00
)
 
$
(0.00
)
                                 
Weighted average number of common shares outstanding (basic and diluted)
   
257,952,433
     
247,148,085
     
255,722,222
     
245,315,070
 

 



See Notes to Financial Statements
 
4


PROTOKINETIX, INCORPORATED
STATEMENT OF STOCKHOLDERS’ EQUITY
(Unaudited)
For the Period from December 31, 2017 to September 30, 2018


   
Common Stock
   
Additional
Paid-in
   
Accumulated
       
   
Shares
   
Amount
   
capital
   
deficit
   
Total
 
Balance, December 31, 2017
   
251,352,433
   
$
1,344
   
$
30,506,094
   
$
(30,133,903
)
 
$
373,535
 
                                         
Issuance of common stock pursuant to private placement offering
   
4,240,760
     
22
     
212,016
     
-
     
212,038
 
Issuance of common  stock pursuant to settlement of promissory notes
   
2,359,240
     
13
     
117,949
             
117,962
 
Fair value of compensatory options issued
   
-
     
-
     
614,427
     
-
     
614,427
 
                                         
Net loss for the period
   
-
     
-
     
-
     
(1,022,677
)
   
(1,022,677
)
                                         
Balance, September 30, 2018
   
257,952,433
   
$
1,379
   
$
31,450,486
   
$
(31,156,580
)
 
$
295,285
 

 



See Notes to Financial Statements
 
5


PROTOKINETIX, INCORPORATED
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
(Unaudited)
For the Nine Months Ended September 30, 2018 and 2017


   
Nine Months ended
September 30, 2018
   
Nine Months ended
September 30, 2017
 
             
CASH FLOWS USED IN OPERATING ACTIVITIES
           
Net loss for the period
 
$
(1,022,677
)
 
$
(1,006,051
)
Adjustments to reconcile net loss to cash used in operating activities:
               
Amortization – intangible assets
   
2,250
     
2,250
 
Fair value of compensatory options granted
   
614,427
     
587,077
 
             Interest accrued
   
306
     
-
 
Changes in operating assets and liabilities:
               
Prepaid expenses and deposits
   
(51,043
)
   
(42,953
)
Accounts payable and accrued liabilities
   
(21,886
)
   
(25,034
)
                 
Net cash used in operating activities
   
(376,537
)
   
(484,711
)
                 
CASH FLOWS USED IN INVESTING ACTIVITIES
               
Purchase of intangible assets
   
(27,946
)
   
(40,176
)
                 
Net cash used in investing activities
   
(27,946
)
   
(40,176
)
                 
                 
CASH FLOWS FROM FINANCING ACTIVITIES
               
Issuance of common stock for cash
   
212,038
     
540,000
 
                 
Net cash from financing activities
   
212,038
     
540,000
 
                 
Net change in cash
   
(192,445
)
   
(15,113
)
                 
Cash, beginning of period
   
302,942
     
371,029
 
                 
Cash, end of period
 
$
110,497
   
$
386,142
 
                 
Cash paid for interest
 
$
-
   
$
-
 
                 
Cash paid for income taxes
 
$
-
   
$
-
 
 Supplementary information – non-cash transactions:
               
Common stock issued to settle promissory notes
 
$
117,962
   
$
-
 
Intangible asset costs previously included in accounts payable and accrued liabilities
   
-
     
3,631
 
Intangible asset costs previously included in prepaid expenses and deposits
   
-
     
15,614
 
Intangible asset costs included in accounts payable and accrued liabilities
   
-
     
3,188
 
See Notes to Financial Statements
 
6


PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018

Note 1.  Basis of Presentation – Going Concern Uncertainties

ProtoKinetix, Incorporated (the “Company”), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999.  The Company is a medical research company whose mission is the advancement of human health care.

The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins (“AFGP”) or anti-aging glycoproteins, trademarked AAGP.  During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).

During the year ended December 31, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the British Columbia Securities Commission (“BCSC”).

The Company’s financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at September 30, 2018.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities.  Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective.  Management is presently engaged in seeking additional working capital through equity financing or related party loans.

The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K, filed March 9, 2018, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

 
7



PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018

Note 2. Summary of Significant Accounting Policies (cont’d)

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.

Cash

Cash consists of funds held in checking accounts.  Cash balances may exceed federally insured limits from time to time.

Fair Value of Financial Instruments

Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.

The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Level 1 inputs are used to measure cash. At September 30, 2018, there were no other assets or liabilities subject to additional disclosure.

Income Taxes

The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.”  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.


 
8


PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018

Note 2. Summary of Significant Accounting Policies (cont’d)

Intangible assets – patent and patent application costs

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.

As at September 30, 2018, the Company does not hold any intangible assets with indefinite lives.

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2018.

Research and Development Costs

Research and development costs are expensed as incurred.

Loss per Share and Potentially Dilutive Securities

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 43,900,000 stock options (September 30, 2017 – 55,100,000), 6,500,000 warrants (September 30, 2017 – 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company’s losses.

Share-Based Compensation

The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.


 
9


PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018

Note 2. Summary of Significant Accounting Policies (cont’d)

Share-Based Compensation   (cont’d)

The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Common stock

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete.

Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

Related Party Transactions

A related party is generally defined as (i) any person that holds 10% or more of the Company’s securities and their immediate families, (ii) the Company’s management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Recent Accounting Pronouncements

Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which went into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The adoption of this guidance did not have a material impact on the Company’s financial statements.

 
10



PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018


Note 2. Summary of Significant Accounting Policies (cont’d)
Recent Accounting Pronouncements   (cont’d)

Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.
 
Note 3.   Prepaid Expenses and Deposits
 
The following summarizes the Company’s prepaid expenses and deposits outstanding as at September 30, 2018 and December 31, 2017:

   
September 30,
2018
   
December 31,
2017
 
             
Deposit on research agreements (Note 11(c))
 
$
10,034
   
$
61,077
 
Other prepaid expenses
   
1,050
     
1,050
 
                 
   
$
11,084
   
$
62,127
 
 
11


PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018

Note 4.   Intangible Assets
 
Intangible asset transactions are summarized as follows:

   
Patent Rights
   
Patent Application
Rights
   
Total
 
Cost
                 
Balance, December 31, 2016
 
$
30,000
   
$
75,181
   
$
105,181
 
Additions
   
-
     
55,347
     
55,347
 
Balance, December 31, 2017
 
$
30,000
   
$
130,528
   
$
160,528
 
Additions
   
-
     
27,946
     
27,946
 
Balance, September 30, 2018
 
$
30,000
   
$
158,474
   
$
188,474
 
                         
Accumulated amortization
                       
Balance, December 31, 2016
 
$
4,500
   
$
-
   
$
4,500
 
Amortization
   
3,000
     
-
     
3,000
 
Balance, December 31, 2017
 
$
7,500
   
$
-
   
$
7,500
 
Amortization
   
2,250
     
-
     
2,250
 
Balance, September 30, 2018
 
$
9,750
   
$
-
   
$
9,750
 
                         
Net carrying amounts
                       
December 31, 2017
 
$
22,500
   
$
130,528
   
$
153,028
 
September 30, 2018
 
$
20,250
   
$
158,474
   
$
178,724
 

During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the “Patent Assignment”) with the Institut National des Sciences Appliquees de Rouen (“INSA”) for the assignment of certain patents and all rights associated therewith (the “Patents”). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the nine month period ended September 30, 2018, the Company recorded $2,250 (2017 - $2,250) in amortization expense associated with the Patents.

During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the “Patent Application Rights”).  In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company’s common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company has incurred $123,474 in direct costs relating to the Patent Application Rights, $27,946 of which were incurred during the nine month period ended September 30, 2018.

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.


 
12


PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2018

Note 4.  Intangible Assets (cont’d)

During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells” (the “New Patent Application Rights”).  In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid).  The Company incurred $2,415 in direct costs relating to the New Patent Application Rights during the year ended December 31, 2016. No amortization was recorded on the Patent Application Rights to September 30, 2018.

Note 5.  Credit Facility

On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia.  Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly.  The Company’s President and CEO pledged personal assets to secure the line of credit and the Company pledged its patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells”.  During the year ended December 31, 2017, the line of credit was canceled, and the pledged assets were released.  As at September 30, 2018 and December 31, 2017, the balance outstanding was $nil.

Note 6.  Common Shares Issued for Services

During the nine month periods ended September 30, 2018 and 2017, the Company did not issue shares of common stock for services or other value.

Note 7.  Stock Options

On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”).  The Board of Directors adopted the 2017 Plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward.

The aggregate number of shares that may be issued under the 2017 Plan is 30,000,000 shares subject to adjustment as provided therein.  The 2017 Plan includes two types of options.  Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended are referred to as incentive options.  Options which are not intended to qualify as incentive options are referred to as non-qualified options.



 
13


PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018


Note 7.  Stock Options (cont’d)
 
As of September 30, 2018, 25,600,000 options and no shares of common stock have been granted and are outstanding under the 2017 Plan.

The 2017 Plan is administered by the Board of Directors, or a committee appointed by the Board of Directors.  In addition to determining who will be granted options or stock bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted.  The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the 2017 Plan.  The committee may determine the purchase price of the shares of common stock covered by each option.  The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the 2017 Plan.  The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the 2017 Plan. 

In the event that a change, such as a stock split, is made in the Company’s capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option.  The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock.  Options and bonuses may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the 2017 Plan shall terminate as of a date fixed by the committee.

The exercise price of any option granted under the 2017 Plan must be no less than 100% of the “fair market value” of the Company’s common stock on the date of grant.  The exercise period of any option shall not exceed ten years from the date of grant of the option. Any incentive stock option granted under the 2017 Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant and the term shall be for no more than five years. 

Stock option transactions are summarized as follows:

   
Number of
Stock Options
   
Weighted Average
Exercise Price
   
Weighted Average
Fair Value
 
Weighted Average Remaining Life
         
$
     
$
   
(Years)
Outstanding, December 31, 2017
   
44,100,000
     
0.06
     
0.05
   
      Options expired
   
(1,600,000
)
   
0.07
     
0.03
   
      Options granted
   
1,400,000
     
0.07
     
0.09
   
Outstanding, September 30, 2018
   
43,900,000
     
0.06
     
0.05
 
2.05


 
14


PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2018

Note 7.  Stock Options (cont’d)

The fair values of the stock options granted during the nine month periods ended September 30, 2018 and 2017
were estimated using the Black-Scholes Option Pricing Model for total share-based compensation expense of $614,427
(2017 - $587,077).  The weighted average assumptions used in the pricing model for these options are as follows:

   
September 30, 2018
   
September 30, 2017
 
Risk-free interest rate
   
1.51
%
   
1.05
%
Dividend yield
   
0.00
%
   
0.00
%
Expected stock price volatility
   
125.00
%
   
125.00
%
Expected forfeiture rate
   
0.00
%
   
0.00
%
Expected life
 
3.61 years
   
 3.46 years
 

The following non-qualified stock options were outstanding and exercisable at September 30, 2018:

Expiry date
 
Exercise Price
   
Number of Options
Outstanding
   
Number of
Options
Exercisable
 
               
$ 
 
February 25, 2020
   
0.04
     
2,000,000
     
-
 
February 28, 2020
   
0.04
     
5,000,000
     
5,000,000
 
December 31, 2019
   
0.08
     
11,000,000
     
11,000,000
 
October 05, 2018
   
0.08
     
300,000
     
300,000
 
December 31, 2020
   
0.05
     
12,200,000
     
12,200,000
 
August 31, 2021
   
0.06
     
11,000,000
     
11,000,000
 
November 14, 2021
   
0.07
     
1,000,000
     
750,000
 
December 31, 2022
   
0.06
     
800,000
     
600,000
 
August 31, 2023
   
0.08
     
600,000
     
-
 
             
43,900,000
     
40,850,000
 

As at September 30, 2018, the aggregate intrinsic value of the Company’s stock options is $2,209,000 (December 31, 2017 – $272,000). The weighted average fair value of stock options granted during the nine month period ended September 30, 2018 is $0.09 (2017 - $0.06).

Note 8.  Warrants

Warrant transactions for the nine month periods ended September 30, 2018 are summarized as follows:
 
 
Number of
Warrants
 
Weighted Average Exercise
Price
 
Balance, December 31, 2017 and September 30, 2018
   
6,500,000
   
$
0.11
 


 
15

PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018

Note 8.  Warrants (cont’d)

The following warrants were outstanding and exercisable as at September 30, 2018:

Number of Warrants
   
Exercise Price ($)
 
Expiry Date
 
500,000
     
0.25
 
November 8,2018
 
6,000,000
     
0.10
 
April 22, 2020
 
6,500,000
         
   


Note 9.  Stockholders’ Equity
 
The Company is authorized to issue 400,000,000 (December 31, 2017 – 400,000,000) shares of $0.0000053 par value common stock.  Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of September 30, 2018 (December 31, 2017 - $nil).

During the nine month period ended September 30, 2018, the Company:

a)    Issued 4,240,760 shares of common stock to investors at $0.05 for gross proceeds of $212,038.

b)   Issued 2,359,240 shares of common stock to the Company’s President and CEO to settle two promissory notes (plus accrued interest) totaling $117,962. No gain or loss was realized on this transaction.
 
Note 10. Related Party Transactions and Balances
 
During the nine months ended September 30, 2017, the Company:

a)
Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2017. The agreement also stipulated a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control.  In addition, the agreement stipulated that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of a sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement.  Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share.  The options vested in equal instalments on a quarterly basis beginning March 31, 2017. On September 1, 2017, the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew. The consulting agreement was also amended to grant an additional 5,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7). The options vest quarterly in equal installments beginning December 31, 2017.



 
16



PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018


Note 10. Related Party Transactions and Balances (cont’d)
 
b)
Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s former CFO whereby she was to be compensated at a monthly fee of $6,000 for services through to December 31, 2017.  The agreement also stipulated a termination fee that would pay the Company’s CFO $72,000 per year of service (including the pro-rata amount for partial years of service) if terminated without cause or upon termination due to a change of control event.  Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7).  The options vested in equal instalments on a quarterly basis beginning March 31, 2017.  A total of $54,000 was paid to the Company’s CFO during the period ended September 30, 2017.

c)
Entered into a directorship agreement with an effective date of January 1, 2017 with a director of the Company.  Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7).  The options vested in equal instalments on a quarterly basis beginning March 31, 2017. On September 1, 2017, the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew. The consulting agreement was also amended to grant an additional 1,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7). The options vest quarterly in equal installments beginning December 31, 2017.

d)
Recognized $297,412 in share-based compensation associated with stock options granted to key management personnel.

During the nine months ended September 30, 2018, the Company:

a)
On November 14, 2017, the Company entered into a consulting agreement with the newly appointed CFO whereby he will be compensated at a monthly fee of $5,000.   Pursuant to the agreement, he was also granted 1,000,000 stock options exercisable into common shares of the Company until November 14, 2021 at a price of $0.07 per share (Note 7). The options vest in equal instalments on a quarterly basis beginning February 14, 2018.  A total of $45,000 was paid or accrued to the Company’s CFO during the period ended September 30, 2018 which is included in professional fees.

b)
Issued a total of 2,359,240 shares of common stock to its President and CEO as settlement of principal and interest owing on two promissory notes (Note 9).

c)
Recognized $297,044 in share-based compensation associated with stock options granted to key management personnel.

As at September 30, 2018 and December 31, 2017, the following amounts are due to related parties:

 
  
 
September 30,
2018
   
December 31,
2017
 
Clarence Smith (CEO)
Promissory notes payable (and interest)
 
$
-
   
$
117,656
 




 
17


PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018


Note 11.  Commitments and Contingency
 
As at September 30, 2018, the Company has the following commitments:

a)
Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $7,000 per month for providing research and development services.  Pursuant to the agreement, the consultant was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2017. On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew. The consulting agreement was also amended to grant an additional 5,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7).  The options vested quarterly in equal installments beginning December 31, 2017.

b)
Entered into a consulting agreement for business development services effective January 1, 2017.  The consultant was granted 1,200,000 stock options exercisable into common shares of the Company at a price of $0.05 per share until December 31, 2020 (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2017.

c)
Entered into a Collaborative Research Agreement (the “CREA”) effective May 31, 2016 with The University of British Columbia (“UBC”) for a term of 2 years. Pursuant to the CREA, the Company paid a total of CAD $169,000 ($131,448) in advance for services to be provided by UBC in the first year, as well as an additional CAD $201,500 ($146,585) within 12 months from the effective date of the CREA in advance of services to be provided by UBC in the second year. The CREA can be terminated by either party with 30 days’ written notice.  As at September 30, 2018, a total of $Nil is included in prepaid expenses and deposits (December 31, 2017 - $61,077).  On January 4, 2018, the Company entered into an additional agreement with UBC. Pursuant to this additional agreement, the Company paid CAD $50,001 ($40,140) for research services to be provided over a term of 1 year. As at September 30, 2018, a total of $10,034 is included in prepaid expenses and deposits pertaining to this additional agreement. On June 29, 2018, the Company entered into an additional agreement with UBC. Pursuant to this additional agreement, the Company paid CAD $54,600 ($41,369) for research services to be provided with an additional installment due in December 2018. As of September 30, 2018, a total of $Nil remains in prepaid expenses and deposits pertaining to this agreement.

d)
Entered into a consulting agreement effective January 1, 2018, whereby the Company would pay the consultant $1,000 per month for a term of 1 year, unless otherwise terminated by either party with at least 30 days’ notice, for providing public relations services. The consultant was also granted 400,000 stock options exercisable into common shares of the Company until December 31, 2022 at a price of $0.06 per share (Note 7). The options vest in equal instalments on a quarterly basis beginning March 31, 2018.

e)
Entered into a royalty agreement with the Governors of the University of Alberta (the “University”) whereby the University had developed certain intellectual property (the “Additional Patent Rights”) in conjunction with and by permission of the Company employing patented intellectual property of the Company. The agreement assigns the Additional Patent Rights to the Company in return for 5% of any future gross revenues (the “Royalty”) derived from products arising from the Patent Rights. The Company had the right to buy out all of the University’s Royalty for consideration of the aggregate sum of CAD $5,000,000, however, the option expired during the year ended December 31, 2017.
f)
Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days’ notice for providing research and development services.  During the nine month period ended September 30, 2017 the contract was revised whereby the Company would pay the consultant CAD $4,000 per month retroactively beginning January 1, 2017.
 
18



PROTOKINETIX, INCORPORATED
(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS
September 30, 2018


Note 11.  Commitments and Contingency (cont’d)

The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, “Report of Foreign Bank and Financial Accounts” (“FBARs”). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs.  Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities.  On November 30, 2017, the Company received a letter from the IRS concluding their review of the Company’s tax returns under the program and accepting the returns as filed.  No penalties have been assessed by the IRS to date, and management does not believe that the Company will incur any penalties relating to the tax years submitted under the program.


 
19




Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context requires otherwise, references in this document to “ProtoKinetix”, “we”, “our”, “us” or the “Company” are to ProtoKinetix, Incorporated.

The following discussion provides information regarding the results of operations for the nine month period ended September 30, 2018 and 2017, and our financial condition, liquidity and capital resources as of September 30, 2018, and December 31, 2017.  The financial statements and the notes thereto contain detailed information that should be referred to in conjunction with this discussion.

Cautionary Note Regarding Forward-Looking Statements
The information discussed in this Quarterly Report on Form 10-Q include “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”).  All statements, other than statements of historical facts, included herein and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases.  Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Our results could differ materially from those anticipated in these forward looking statements as a result of certain factors, including, among others:

•
Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;
•
Our plans to develop and commercialize products from the AAGP® molecule;
•
Ongoing testing of the AAGP® molecule;
•
Our intellectual property position;
•
Our commercialization, marketing and manufacturing capabilities and strategy;
•
Our ability to retain key members of our senior management and key scientific consultants;
•
The effects of competition;
•
Our potential tax liabilities resulting from conducting business in the United States and Canada;
•
The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock; and
•
Our common stock’s limited trading history.

Finally, our future results will depend upon various other risks and uncertainties, including, but not limited to, those detailed in our filings with the SEC under the Exchange Act and the Securities Act, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.  All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph and elsewhere in this Quarterly Report. Other than as required under securities laws, we do not assume a duty to update these forward looking statements, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.


Business Overview

ProtoKinetix, Incorporated is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGP®.  The Company has recently been in the process of directing major efforts to the practical side of commercial validation.  The commercial applications for AAGP® in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP® to market.

 
20

Results of Operations

The following table shows selected financial data and operating results for the periods noted.  Following the table, please see management’s discussion of significant changes.
 
   
For the Nine Months Ended
 
   
September 30,
 
   
2018
   
2017
 
Operating Expenses
           
Amortization
 
$
2,250
   
$
2,250
 
General and administrative
   
56,757
     
74,437
 
Professional fees
   
98,274
     
109,823
 
Research and development
   
247,896
     
228,130
 
Share-based compensation
   
614,427
     
587,077
 
Total Operating Expenses
   
1,019,604
     
1,001,717
 
Loss from Operations
   
(1,019,604
)
   
(1,001,717
)
                 
Other Income
               
Foreign Exchange Loss
   
(3,073
)
   
(4,334
)
Total Other Income
   
(3,073
)
   
(4,334
)
Net Loss
 
$
(1,022,677
)
   
(1,006,051
)
 
Revenues
We had no revenues for the nine month periods ended September 30, 2018 and 2017.

Gross Profit and Expenses
The Company’s net loss was $1,022,677 for the nine month period ended September 30, 2018 compared to $1,006,051 for the nine month period ended September 30, 2017.  These expenses were primarily incurred for professional fees, consulting services related to the operations of the Company’s business, research and development and other general and administrative expenses.  Significant changes from the prior nine month period ended September 30, 2017 include:

General and administrative fees decreased by $17,680 from $74,437 to $56,757 primarily as a result of a decrease in spending on advertising and public relations.
·
Research and development increased year over year with by $19,766 from $228,130 to $247,896 with the primary spending being testing of effects of glycopeptides on bone marrow stem cell engraphment and antibody production and retinal cell transplants with the University of British Columbia.
·
Share-based compensation increased by $27,350 from $587,077 to $614,427 primarily as a result of an increase in pricing for management stock options for the current year.

Liquidity and Capital Resources
 
The following summarizes our statements of cash flows at September 30, 2018 and December 31, 2017:

   
September 30,    2018
   
December 31, 2017
 
Cash
 
$
110,497
   
$
302,942
 
                 
Working Capital
 
$
116,561
   
$
220,507
 

At September 30, 2018, we had $110,497 in cash and $121,581 in total current assets.  As of September 30, 2018, we had a working capital equity position of $116,561. Based upon our working capital equity as of September 30, 2018, we require additional equity and/or debt financing in order to meet cash flow projections and carry forward our business objectives.   

There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our new business. The failure to secure adequate outside funding would have an adverse effect on our plan of operation and results therefrom and a corresponding negative impact on stockholder liquidity.
 

 
21
Sources and Uses of Cash

Net Cash Used in Operating Activities

Net cash used in operating activities decreased by $108,174 from $484,711 to $376,537 for the nine months ended September 30, 2017 and 2018, respectively.  This decrease was predominantly due to a decrease in compensatory stock options awarded to management.

Net Cash Used in Investing Activities

Net cash used in investing activities was $27,946 for the nine month period ended September 30, 2018 while the Company had net cash used in investing activities of $40,176 for the comparative period.  The difference is attributable to a decrease in the purchase of intangible assets.

Net Cash Provided by Financing Activities

Net cash provided by financing activities decreased by $327,962 from $540,000 to $212,038 for the nine months ended September 30, 2017 and 2018, respectively due to a decline in funding from private placements.

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), which contemplate continuation of the Company as a going concern.  The history of losses and the inability for the Company to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern. In spite of the fact that the current cash obligations of the Company are relatively minimal, given the cash position of the Company, we have very little cash to operate. We intend to fund the Company and attempt to meet corporate obligations by selling common stock.  However, the Company’s common stock is at a low price and is not actively traded.

Off-Balance Sheet Arrangements

None.

Contractual Obligations

As a smaller reporting company, we are not required to provide the information required by paragraph (a)(5) of this Item.

Critical Accounting Policies

The preparation of financial statements in conformity with U.S. GAAP requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements.


 
22





Our management routinely makes judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operation and/or financial condition. Our significant accounting policies are disclosed in Note 2 to the Financial Statements included in this Form 10-Q.

While all of the significant accounting policies are important to the Company’s financial statements, the following accounting policies and the estimates derived there from have been identified as being critical.

Share-Based Compensation

On July 1, 2015, the Board of Directors of the Company adopted the 2015 Stock Option and Stock Bonus Plan (the “Plan”).  The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services outside of the Plan, and beginning July 1, 2015 and ending December 31, 2016 pursuant to the Plan.  On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”). During the nine month period ended September 30, 2018, the Company granted options to purchase a total of 1,400,000 shares of common stock to two consultants pursuant to the 2017 Plan.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.

The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Sales and Marketing

The Company is currently not selling or marketing any products.

Inflation

Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the nine months ended September 30, 2018.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.



 
23


Item 4: Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (the “1934 Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the 1934 Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, under the direction of our Chief Executive Officer (who is our principal executive officer), and Chief Financial Officer (who is our principal accounting officer) has evaluated the effectiveness of our disclosure controls and procedures as required by 1934 Act Rule 13a-15(b) as of September 30, 2018 (the end of the period covered by this report).  Based on that evaluation, our principal executive officer and our principal accounting officer concluded that these disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosure and are effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

The Company, including its Chief Executive Officer and Chief Financial Officer, does not expect that its internal controls and procedures will prevent or detect all error and all fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) promulgated by the SEC under the 1934 Act) during the nine months ended September 30, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


 
24



PART II - OTHER INFORMATION
Item 1. Legal Proceedings

Other than previously reported, the Company and its management are not aware of any regulatory or legal proceedings or investigations pending involving the Company, any of its subsidiaries or affiliates, or any of their respective officers, directors or employees.

Item 1A. Risk Factors

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.  However, our current risk factors are set forth in our Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the SEC on March 9, 2018, and such risk factors are incorporated herein by this reference.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
 
On September 1, 2018, the Company issued options to purchase a total of 600,000 shares of common stock at $0.08 per share to one consultant pursuant to the 2017 Plan.  For this grant of options, no solicitation was used and the Company relied on the exemption from registration available under Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and/or Rule 506(b) of Regulation D promulgated under the 1933 Act with respect to transactions by an issuer not involving any public offering.  No commissions were paid in connection with these issuances of securities.

Other than previously reported, there have been no unregistered sales of equity securities during the nine month period ended September 30, 2018.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information

None.
 
25



Item 6. Exhibits

The following is a complete list of exhibits filed as part of this Form 10-Q.  Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

 
EXHIBIT INDEX
The following documents are being filed with the Commission as exhibits to this Quarterly Report on Form 10-Q.
Exhibit
 
Description
 
 
 
 
 
 
 
 
10.5  
 
 
 
 
 
 
31.2
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Schema Document 
101.CAL
 
XBRL Calculation Linkbase Document 
101.DEF
 
XBRL Definition Linkbase Document 
101.LAB
 
XBRL Label Linkbase Document
101.PRE
 
XBRL Presentation Linkbase Document  
 
1.
Incorporated by reference from the Company’s registration statement on Form 10-SB filed on June 22, 2001 with the SEC.
2.
Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on August 14, 2015 with the SEC.
3.
Incorporated by reference from the Company’s Annual Report on Form 10-K filed on February 21, 2017 with the SEC.
4.
Incorporated by reference from the Company’s Annual Report on Form 10-K filed on April 14, 2015 with the SEC.
5.
Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on August 15, 2016 with the SEC.
6.
Incorporated by reference from the Company’s Annual Report on Form 10-K filed on April 13, 2006 with the SEC.
7.
Incorporated by reference from the Company’s Current Report on Form 8-K filed on November 15, 2017 with the SEC.
8.
Incorporated by reference from the Company’s amended Current Report on Form 8-K filed on September 12, 2017 with the SEC.
9.
Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on November 13, 2017 with the SEC.
*.
Filed herewith.
**
Furnished, not filed herewith.


 
26




 SIGNATURES
 
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 25, 2018
 
PROTOKINETIX, INCORPORATED
     
   
By: /s/ Clarence E. Smith
   
Clarence E. Smith
   
Chief Executive Officer
     
   
By: /s/ Michael Guzzetta
   
Michael Guzzetta
   
Chief Financial Officer


 
27
 



EXHIBIT 31.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Clarence E. Smith, certify that:
 
1.  I have reviewed this Quarterly Report on Form 10-Q of ProtoKinetix, Incorporated for the period ended September 30, 2018;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.  The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
October 25, 2018
 
/s/ Clarence E. Smith
   
Name:
Clarence E. Smith
   
Title:
Chief Executive Officer
(Principal Executive Officer)






EXHIBIT 31.2
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael R. Guzzetta, certify that:
 
1.  I have reviewed this Quarterly Report on Form 10-Q of ProtoKinetix, Incorporated for the period ended September 30, 2018;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c)  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d)  Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.  The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 

 
October 25, 2018
 
/s/ Michael R. Guzzetta
   
Name:
Michael R. Guzzetta
   
Title:
Chief Financial Officer
(Principal Financial Officer)
 




EXHIBIT 32
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of ProtoKinetix, Incorporated, (the “Company”) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Clarence E. Smith, Chief Executive Officer and Principal Executive Officer of the Company and Michael R. Guzzetta, Chief Financial Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:
 
1.  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.
 
       
October 25, 2018
By:
/s/ Clarence E. Smith  
  Name:     
Clarence E. Smith
 
  Title: 
Chairman of the Board and
Chief Executive Officer
(Principal Executive Officer)
 
       

 
       
October 25, 2018
By:
/s/ Michael R. Guzzetta  
  Name:      
Michael R. Guzzetta
 
  Title: 
Chief Financial Officer
(Principal Financial Officer)
 
       
This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.